At a glance
ClinicalIndex Comparison RecordPhase 3Unknown· 122 target
Drug / intervention
Busulfan (BU) +2 moredrug
Likely dose
Busulfan (BU) 3.2 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation
Nanfang Hospital, Southern Medical University·interventional·Posted Jul 25, 2017·Updated Oct 12, 2017
In Brief
A Phase 3 clinical trial evaluating Busulfan (BU), Cyclophosphamide (CY), and 1 other intervention for Autologous Hematopoietic Stem Cell Transplantation and 2 related conditions. Targeting 122 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of BUCY+VP-16 and BUCY myeloablative conditioning regimens in diffuse large B-cell lymphoma undergoing autologous hematopoietic stem cell transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma, Conditioning
CountriesChina
Timeline
Phase 3UnknownOverdue
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedJul 2017
Primary CompletionJun 2020
TodayJul 2026
First PostedJul 25, 2017
Enrollment StartJul 5, 2017
Primary CompletionJun 1, 2020
TodayJul 1, 2026
Enrollment to primary: 2.9 yearsPosted 8.9 years ago
Interventions
Busulfan (BU)drug
Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Cyclophosphamide (CY)drug
Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Etoposide (VP-16)drug
Etoposide was administered at 15 mg/kg/day on days -3 to -2.